Part,  Chapter, Paragraph

 1    -,     1            |         Organizations (Appendix 1); (iii) reviewed by the experts
 2    -,     1            |    Introduction; (ii) Data sources; (iii) Data description and analysis; (
 3    I,     2.  1        |            ii) higher labour supply;(iii) improved skills as a result
 4   II,     5.  2.  7    |        Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol
 5   II,     5.  4.  2    |         tolerance and/or diet only~2~III Risk factors for complications~ ~
 6   II,     5.  5.Int    |           Disabilities in 2003; and (iii) The adoption of a European
 7   II,     5.  5.  3    |             disease progression, and iii) the majority of the cost
 8   II,     5.  5.  3    |            couple in the community; (iii) living or staying in nursing
 9   II,     5.  6.  6    |              O'Fallon WM, Melton LJ, III (1993): Population-based
10   II,     5.  6.  6    |            1005~Cooper C, Melton LJ, III (1992): Epidemiology of
11   II,     5.  6.  6    |           BMJ 317:111-115~Melton LJ, III (1995): Epidemiology of
12   II,     5.  6.  6    |             by: Riggs BL, Melton LJ, III). Lippincott-Raven Publishers,
13   II,     5.  6.  6    |     Publishers, pp 225-47~Melton LJ, III (2003): Adverse outcomes
14   II,     5.  7.Acr    |              in Renal Disease~NHANES III~National Health and Nutrition
15   II,     5.  7.Acr    |         Nutrition Examination Survey III~PD~Peritoneal Dialysis~PMARP~
16   II,     5.  7.  1    |         Nutrition Examination Survey III (NHANES III) show that about
17   II,     5.  7.  1    |       Examination Survey III (NHANES III) show that about 1 out 10
18   II,     5.  7.  3    |              made in the USA (NHANES III and NHANES IV performed
19   II,     5.  7.  3    |              rose from 14.5% (NHANES III) to 16.8% (NHANES IV) (Tonelli
20   II,     5.  7.  7    |         gender: evidence from NHANES III. Ann Epidemiol 2007 Jan;
21   II,     5.  8.  3    |     respectively for stage I, II and III of the diseases.~ ~In the
22   II,     5.  8.  3(27)|            FEV1 <80% predicted~Stage III:~Severe FEV1/FVC <0.70~30%
23   II,     5.  9.  2    |             to 11 years. ISAAC Phase III is the continuation of this
24   II,     5.  9.  4    |  pteronyssinus; (ii) timothy grass; (iii) cat; (iv) Cladosporium
25   II,     5.  9.  7    |            and conjunctivitis: Phase III of the International Study
26   II,     5. 11.  6    |            becoming more common; and iii) that future demand for
27   II,     7.  5        |           surveillance instruments; (iii) to strengthen the technical
28   II,     9.  2.  5    |              physical activityRPG III: ensure clean outdoor and
29   II,     9.  4.  5    |            couple in the community; (iii) living or staying in an
30  III                   |                                 PART III~HEALTH CAUSES, FACTORS AND
31  III,    10.  2.  1    |               ii) problem drug use; (iii) drug related infectious
32  III,    10.  2.  1    | health-promoting school activities; (iii) for those countries without
33  III,    10.  2.  1    |             be added to foods. Annex III is a list of substances
34  III,    10.  4.  2    |           and specified in its Annex III, Chapter A. At the beginning
35  III,    10.  4.  2    |              in Chapter B.I of Annex III of the TSE Regulation, Member
36  III,    10.  4.  2    |              250 substance);~· Annex III deals with temporary MRLs
37  III,    10.  4.  2    |          latest draft Annexes II and III which specify the data required
38   IV,    11.  6.  5    |            al. (2005): Mental health III: Funding mental health in
39   IV,    12.  4        |           position July 2007)~Daphne III (combating violence against
40   IV,    12.  6        |     professionals and trade unions; (iii) health service providers
41   IV,    12. 10        |                ii) older people and (iii) disability and mental health
42   IV,    13.  7.  3    |          European Research Council; (iii) strengthening the human